Infectious Diseases

>

Latest News

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age | Image credit: Contemporary Pediatrics
FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

June 12th 2025

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD

June 12th 2025

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention

June 10th 2025

FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics
FDA approves clesrovimab to protect infants during first RSV season

June 9th 2025

Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD
Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD

June 6th 2025

Latest CME Events & Activities

A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology

View More

Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age

View More

Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

<1
...
3132333435
© 2025 MJH Life Sciences

All rights reserved.